Tonix Pharmaceuticals Holding (TNXP) Income towards Parent Company: 2017-2024
Historic Income towards Parent Company for Tonix Pharmaceuticals Holding (TNXP) over the last 8 years, with Dec 2024 value amounting to -$136.7 million.
- Tonix Pharmaceuticals Holding's Income towards Parent Company fell 101.02% to -$31.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$98.0 million, marking a year-over-year increase of 30.87%. This contributed to the annual value of -$136.7 million for FY2024, which is 39.20% down from last year.
- Tonix Pharmaceuticals Holding's Income towards Parent Company amounted to -$136.7 million in FY2024, which was down 39.20% from -$98.2 million recorded in FY2023.
- Tonix Pharmaceuticals Holding's Income towards Parent Company's 5-year high stood at -$41.2 million during FY2020, with a 5-year trough of -$136.7 million in FY2024.
- Moreover, its 3-year median value for Income towards Parent Company was -$98.2 million (2023), whereas its average is -$107.8 million.
- Data for Tonix Pharmaceuticals Holding's Income towards Parent Company shows a maximum YoY plummeted of 81.86% (in 2020) over the last 5 years.
- Tonix Pharmaceuticals Holding's Income towards Parent Company (Yearly) stood at -$41.2 million in 2020, then slumped by 79.05% to -$73.7 million in 2021, then decreased by 20.07% to -$88.5 million in 2022, then decreased by 10.99% to -$98.2 million in 2023, then slumped by 39.20% to -$136.7 million in 2024.